Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.

Itskovitz-Eldor J, Kol S, Mannaerts B

Human reproduction (Oxford, England)1 Sept 2000Cited by 138 (Europe PMC)

PMID10966996DOI10.1093/humrep/15.9.1965PepBankPUB-10966996

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. 2 results from people.

01HumanCase report or seriesEfficacy outcome
In eight women at risk of OHSS having rFSH stimulation with ganirelix, a single 0.2 mg triptorelin injection was followed by an endogenous LH surge with a median peak of 219 IU/l.
In plain wordsIn women having ovarian stimulation, a triptorelin injection was followed by a surge of the body's own LH.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLH surge
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Median peak LH
219 IU/l
4 h after injection
Source sentences
Summary
After GnRH agonist injection, endogenous serum LH and FSH surges were observed with median peak values of 219 and 19 IU/l respectively, measured 4 h after injection.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes the use of 0.2 mg triptorelin (Decapeptyl) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran) for the prevention of premature LH surges.
Report a problemFND-1096699601
02HumanCase report or seriesEfficacy outcome
In eight women at risk of OHSS having rFSH stimulation with ganirelix, a single 0.2 mg triptorelin injection was followed by an endogenous FSH surge with a median peak of 19 IU/l.
In plain wordsIn women having ovarian stimulation, a triptorelin injection was followed by a surge of the body's own FSH.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFSH surge
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Median peak FSH
19 IU/l
4 h after injection
Source sentences
Summary
After GnRH agonist injection, endogenous serum LH and FSH surges were observed with median peak values of 219 and 19 IU/l respectively, measured 4 h after injection.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes the use of 0.2 mg triptorelin (Decapeptyl) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran) for the prevention of premature LH surges.
Report a problemFND-1096699602

Studies that did not test the peptide alone5

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome
In women receiving the recombinant FSH, ganirelix, and triptorelin regimen, the mean number of oocytes obtained was 23.4.
In plain wordsIn women, the recombinant FSH, ganirelix, and triptorelin regimen yielded a mean of 23.4 oocytes.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOocytes obtained
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Mean oocytes
23.4 oocytes
regimen
Source sentences
Summary
The mean number of oocytes obtained was 23.4 +/- 15.4, of which 83% were mature (metaphase II).
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes the use of 0.2 mg triptorelin (Decapeptyl) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran) for the prevention of premature LH surges.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096699603
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome
In women receiving the recombinant FSH, ganirelix, and triptorelin regimen, 83% of obtained oocytes were mature.
In plain wordsIn women, 83% of oocytes obtained with the recombinant FSH, ganirelix, and triptorelin regimen were mature.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableMature oocytes
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Mature oocytes
83%
metaphase II
Source sentences
Summary
The mean number of oocytes obtained was 23.4 +/- 15.4, of which 83% were mature (metaphase II).
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes the use of 0.2 mg triptorelin (Decapeptyl) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran) for the prevention of premature LH surges.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096699604
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesSafety outcome
No woman developed signs or symptoms of ovarian hyperstimulation syndrome with the recombinant FSH, ganirelix, and triptorelin regimen.
In plain wordsNo woman developed ovarian hyperstimulation syndrome with the recombinant FSH, ganirelix, and triptorelin regimen.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOvarian hyperstimulation syndrome
Study
n = 8
Outcome group
Adverse events · Reproductive and sexual health
Source sentences
Summary
None of the patients developed any signs or symptoms of OHSS.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes the use of 0.2 mg triptorelin (Decapeptyl) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran) for the prevention of premature LH surges.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096699605
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome
Four clinical pregnancies occurred from embryos obtained with the recombinant FSH, ganirelix, and triptorelin regimen.
In plain wordsFour clinical pregnancies occurred from embryos obtained with the recombinant FSH, ganirelix, and triptorelin regimen.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableClinical pregnancies
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
So far, four clinical pregnancies have been achieved from the embryos obtained during these cycles, including the first birth following this approach.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes the use of 0.2 mg triptorelin (Decapeptyl) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran) for the prevention of premature LH surges.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096699606
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome
The recombinant FSH, ganirelix, and triptorelin regimen resulted in the first reported birth with this approach.
In plain wordsThe recombinant FSH, ganirelix, and triptorelin regimen resulted in a reported birth.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableBirth
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
So far, four clinical pregnancies have been achieved from the embryos obtained during these cycles, including the first birth following this approach.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes the use of 0.2 mg triptorelin (Decapeptyl) to trigger ovulation in eight patients who underwent controlled ovarian hyperstimulation with recombinant FSH (rFSH, Puregon) and concomitant treatment with the GnRH antagonist ganirelix (Orgalutran) for the prevention of premature LH surges.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096699607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.